Efficacy of Qingfei Paidu Decoction on Patients with COVID-19 Pneumonia in Wuhan, China: A Propensity Score Matching Study
Table 2
Characteristics of patients with COVID-19 pneumonia after propensity score matching (1 : 1 match).
Variables
QPD
NoQPD
SMD
n
223
223
Sex
Female (%)
112 (50.2)
110 (49.3)
0.018
Age (median [IQR])
59.00 [51.00–66.00]
61.00 [49.00–69.00]
0.001
Symptoms
Fever
179 (80.3)
184 (82.5)
0.058
Dizziness
24 (10.8)
25 (11.2)
0.014
Fatigue
119 (53.4)
121 (54.3)
0.018
Nausea
33 (14.8)
35 (15.7)
0.025
Diarrhea
43 (19.3)
45 (20.2)
0.023
Myalgia
56 (25.1)
62 (27.8)
0.061
Abnormality of mentality
9 (4.0)
8 (3.6)
0.023
Headache
18 (8.1)
15 (6.7)
0.051
Abdominal pain
13 (5.8)
12 (5.4)
0.019
Dyspnea
164 (73.5)
164 (73.5)
<0.001
Cough
174 (78.0)
169 (75.8)
0.053
Sputum
100 (44.8)
90 (40.4)
0.091
Chest pain
14 (6.3)
10 (4.5)
0.080
Comorbidity
Hypertension
43 (19.3)
39 (17.5)
0.046
Diabetes
17 (7.6)
10 (4.5)
0.132
Coronary heart disease
11 (4.9)
14 (6.3)
0.059
COPD
1 (0.4)
1 (0.4)
<0.001
Cancer
6 (2.7)
6 (2.7)
<0.001
Chronic renal disease
0 (0.0)
0 (0.0)
<0.001
Cerebrovascular disease
5 (2.2)
5 (2.2)
<0.001
QPD, Qingfei Paidu decoction; SMD, standardized mean difference; IQR, interquartile range; COPD, chronic obstructive pulmonary disease. All variables except diabetes had SMD values less than 0.1, indicating that the two groups were comparable.
